Celgene
BMS-986368
Multiple Sclerosis Spasticity
Countdown
323days
Phase 2 readout · May 26, 2027
What's at stake
Phase 2 trial results for BMS-986368 in Multiple Sclerosis Spasticity are due May 26, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06782490: Phase 2 trial, sponsor Celgene, drug BMS-986368. Primary completion date 2027-05-26 (estimated).”